FDA.gov The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar lev...
HealthDay The researchers found that around 40 percent of people taking a sulfonylurea, a thiazolidinedione , or a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor) ad...
Diabetes In Control While 24.5% patients on metformin required an add-on oral medication , 37.1% of patients on sulfonylurea, 39.6% of patients on thiazolidinedione , and 36.2% patients on DPP-4 inhibitor required an add-on oral medication . Moreover, 5.1% of patients on ...
Diabetes In Control The medication can be used as monotherapy or in combination with other agents for optimal glycemic control in type 2 diabetes patients. The use of combination therapy utilizes medications that offer different mechanisms of action for improved glycemic ...
Medscape Pioglitazone, a thiazolidinedione (TZD) for the treatment of type 2 diabetes, has been associated with a number of adverse effects, including fractures and fluid retention, and is contraindicated in patients with class 3 or 4 heart failure. But it has ... and more »
MarketWatch Higher frequency of weight gain and edema was observed in patients taking both LYRICA and thiazolidinedione antidiabetic drugs . Exercise caution when coadministering these drugs . Patients who are taking other drugs associated with angioedema such as ... and more »
Medscape Scientists have developed a computer model that can predict how drugs will affect the liver, and they have used it to demonstrate that they could have identified the relatively rare risk for hepatotoxicity with the type 2 diabetes drug troglitazone ...
American Pharmacists Association, pharmacist.com ... as dulaglutide include the low risk of hypoglycemia, especially when administered with metformin or a thiazolidinedione ; the weight-loss effects of these agents; and potential adherence benefits associated with drugs that only require once-weekly ...
